Nutritional Interventions for Patients with Mitochondrial POLG-Related Diseases: A Systematic Review on Efficacy and Safety

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Sep 23

PMID 36142570

Authors

Zandra Overgaard Pedersen

Sonja Holm-Yildiz

Tina Dysgaard

Affiliations

Soon will be listed here.

Abstract

Ketogenic diet is recommended as a treatment to reduce seizure frequency in patients with intractable epilepsy. The evidence and safety results are sparse for diet interventions in patients with pathogenic polymerase gamma (POLG) variants and intractable epilepsy. The aim of this systematic review is to summarize the efficacy of diet treatment on seizure frequency, clinical symptoms, and potential deleterious effect of liver involvement in patients with mitochondrial diseases caused by pathogenic POLG variants. Literature was searched in PubMed, Embase; and Cochrane in April 2022; no filter restrictions were imposed. The reference lists of retrieved studies were checked for additional literature. Eligibility criteria included verified pathogenic POLG variant and diet treatment. Overall, 880 studies were identified, providing eight case-reports representing nine patients eligible for inclusion. In eight of nine cases, clinical symptoms were improved; six out of nine cases reported improvements in seizure frequency. However, increasing levels of liver enzymes after initiating ketogenic diet were found in four of the nine cases, with one case revealing decreased levels of liver enzymes after initiating long-chain triglyceride restriction. Viewed together, the studies imply that ketogenic diet can have a positive impact on seizure frequency, but may induce progression of liver impairment in patients with pathogenic POLG variants.

Citing Articles

Status epilepticus in POLG disease: a large multinational study.

Hikmat O, Naess K, Engvall M, Klingenberg C, Rasmussen M, Brodtkorb E J Neurol. 2024; 271(8):5156-5164.

PMID: 38822839 PMC: 11319559. DOI: 10.1007/s00415-024-12463-5.

Single-Nucleotide Polymorphisms in Genes Maintaining the Stability of Mitochondrial DNA Affect the Occurrence, Onset, Severity and Treatment of Major Depressive Disorder.

Czarny P, Ziolkowska S, Kolodziej L, Watala C, Wigner-Jeziorska P, Blizniewska-Kowalska K Int J Mol Sci. 2023; 24(19).

PMID: 37834200 PMC: 10573273. DOI: 10.3390/ijms241914752.

References

McHugh M . Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012; 22(3):276-82. PMC: 3900052. View

Castro-Gago M, Fernandez-Seara M, Rodrigo-Saez E, Fernandez-Cebrian S, Alonso-Martin A, Campos Y . [Early mitochondrial encephalomyopathy due to complex IV deficiency consistent with Alpers-Huttenlocher syndrome: report of two cases]. Rev Neurol. 2000; 29(10):912-7. View

Kim S, Kang H, Lee E, Lee J, Kim H . Low glycemic index treatment in patients with drug-resistant epilepsy. Brain Dev. 2017; 39(8):687-692. DOI: 10.1016/j.braindev.2017.03.027. View

van der Louw E, Hurk D, Neal E, Leiendecker B, Fitzsimmon G, Dority L . Ketogenic diet guidelines for infants with refractory epilepsy. Eur J Paediatr Neurol. 2016; 20(6):798-809. DOI: 10.1016/j.ejpn.2016.07.009. View

Bachmann-Gagescu R, Merritt 2nd J, Hahn S . A cognitively normal PDH-deficient 18-year-old man carrying the R263G mutation in the PDHA1 gene. J Inherit Metab Dis. 2009; 32 Suppl 1. DOI: 10.1007/s10545-009-1101-4. View

Tzoulis C, Engelsen B, Telstad W, Aasly J, Zeviani M, Winterthun S . The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases. Brain. 2006; 129(Pt 7):1685-92. DOI: 10.1093/brain/awl097. View

Neal E, Chaffe H, Schwartz R, Lawson M, Edwards N, Fitzsimmons G . The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol. 2008; 7(6):500-6. DOI: 10.1016/S1474-4422(08)70092-9. View

Hikmat O, Naess K, Engvall M, Klingenberg C, Rasmussen M, Tallaksen C . The impact of gender, puberty, and pregnancy in patients with POLG disease. Ann Clin Transl Neurol. 2020; 7(10):2019-2025. PMC: 7545595. DOI: 10.1002/acn3.51199. View

van Goethem G, Martin J, Dermaut B, Lofgren A, Wibail A, Ververken D . Recessive POLG mutations presenting with sensory and ataxic neuropathy in compound heterozygote patients with progressive external ophthalmoplegia. Neuromuscul Disord. 2003; 13(2):133-42. DOI: 10.1016/s0960-8966(02)00216-x. View

10.

Daniel R, Singh M, ORourke K . Another "Complex" Case: Complex I Deficiency Secondary to Acyl-CoA Dehydrogenase 9 Mutation. Am J Med Sci. 2015; 350(5):423-4. DOI: 10.1097/MAJ.0000000000000570. View

11.

Sato-Shirai I, Ogawa E, Arisaka A, Osaka H, Murayama K, Kuwajima M . Valine-restricted diet for patients with ECHS1 deficiency: Divergent clinical outcomes in two Japanese siblings. Brain Dev. 2020; 43(2):308-313. DOI: 10.1016/j.braindev.2020.10.003. View

12.

OConnor S, Ream M, Richardson C, Mikati M, Trescher W, Byler D . The ketogenic diet for the treatment of pediatric status epilepticus. Pediatr Neurol. 2013; 50(1):101-3. DOI: 10.1016/j.pediatrneurol.2013.07.020. View

13.

Harun-Or-Rashid M, Inman D . Reduced AMPK activation and increased HCAR activation drive anti-inflammatory response and neuroprotection in glaucoma. J Neuroinflammation. 2018; 15(1):313. PMC: 6234605. DOI: 10.1186/s12974-018-1346-7. View

14.

Wiltshire E, Davidzon G, DiMauro S, Akman H, Sadleir L, Haas L . Juvenile Alpers disease. Arch Neurol. 2008; 65(1):121-4. DOI: 10.1001/archneurol.2007.14. View

15.

Joshi C, Greenberg C, Mhanni A, Salman M . Ketogenic diet in Alpers-Huttenlocher syndrome. Pediatr Neurol. 2009; 40(4):314-6. DOI: 10.1016/j.pediatrneurol.2008.10.023. View

16.

Kanabus M, Fassone E, Hughes S, Farahi Bilooei S, Rutherford T, Donnell M . The pleiotropic effects of decanoic acid treatment on mitochondrial function in fibroblasts from patients with complex I deficient Leigh syndrome. J Inherit Metab Dis. 2016; 39(3):415-426. PMC: 4851692. DOI: 10.1007/s10545-016-9930-4. View

17.

Berio A . [The Kearns-Sayre syndrome]. Pediatr Med Chir. 1994; 16(2):167-71. View

18.

Lutas A, Yellen G . The ketogenic diet: metabolic influences on brain excitability and epilepsy. Trends Neurosci. 2012; 36(1):32-40. PMC: 3534786. DOI: 10.1016/j.tins.2012.11.005. View

19.

Kang H, Lee Y, Kim H, Lee J, Slama A . Safe and effective use of the ketogenic diet in children with epilepsy and mitochondrial respiratory chain complex defects. Epilepsia. 2007; 48(1):82-8. DOI: 10.1111/j.1528-1167.2006.00906.x. View

20.

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339:b2700. PMC: 2714672. DOI: 10.1136/bmj.b2700. View